A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Inclusion Criteria:

Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Male or female participants ≥ 18 years of age (or age ≥ regionally approved age of consent for participation in investigational clinical studies) at the time of signing the informed consent.
Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Adequate organ and marrow function

Exclusion Criteria:

History of trauma or major surgery within 28 days prior to the first dose of study treatment.
Prior treatment with an anti-TIGIT antibody.
Any active or prior autoimmune disease that required treatment within 3 years of the first dose of study treatment.
Prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic agents, or use of other investigational drugs within 28 days before first dose of study treatment.
Discontinued prior immunotherapy for immune related adverse events with a high severity.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.